Research Analysts Set Expectations for CRBU FY2029 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU - Free Report) - Brookline Capital Management issued their FY2029 earnings estimates for Caribou Biosciences in a report issued on Monday, January 6th. Brookline Capital Management analyst L. Cann forecasts that the company will earn $16.92 per share for the year. The consensus estimate for Caribou Biosciences' current full-year earnings is ($1.64) per share.

Several other research firms have also recently commented on CRBU. Citigroup lowered their target price on Caribou Biosciences from $30.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, November 26th. Bank of America lowered their price objective on Caribou Biosciences from $13.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $9.00 price target on shares of Caribou Biosciences in a research note on Friday, November 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Caribou Biosciences currently has a consensus rating of "Buy" and a consensus target price of $10.33.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock traded down $0.15 during trading hours on Wednesday, reaching $1.72. 1,456,877 shares of the company were exchanged, compared to its average volume of 1,470,815. The firm has a market cap of $155.75 million, a PE ratio of -1.04 and a beta of 2.34. Caribou Biosciences has a 1 year low of $1.50 and a 1 year high of $8.33. The stock's fifty day moving average is $2.03 and its 200 day moving average is $2.00.

Caribou Biosciences (NASDAQ:CRBU - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The company had revenue of $2.02 million for the quarter, compared to analyst estimates of $3.37 million.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Erste Asset Management GmbH purchased a new stake in Caribou Biosciences in the third quarter valued at approximately $28,000. AQR Capital Management LLC acquired a new position in shares of Caribou Biosciences in the 2nd quarter valued at $30,000. China Universal Asset Management Co. Ltd. raised its position in Caribou Biosciences by 63.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,380 shares of the company's stock valued at $34,000 after purchasing an additional 6,768 shares during the last quarter. Intech Investment Management LLC acquired a new stake in Caribou Biosciences during the 3rd quarter worth $43,000. Finally, Point72 DIFC Ltd grew its position in Caribou Biosciences by 389.4% during the 2nd quarter. Point72 DIFC Ltd now owns 30,157 shares of the company's stock worth $49,000 after purchasing an additional 23,995 shares during the last quarter. Institutional investors and hedge funds own 77.51% of the company's stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.